See the DrugPatentWatch profile for Wixela
How Much Does Wixela Inhub Cost?
The price of Wixela Inhub, a twice-daily inhalation therapy for COPD, can vary depending on factors such as insurance coverage, pharmacy, and the specific dosage. While exact pricing is not publicly disclosed by the manufacturer, general estimates suggest that a one-month supply can range from approximately $250 to $450 USD [1]. This cost may be reduced through patient assistance programs offered by the manufacturer or by using discount coupons [1].
What Factors Influence Wixela Inhub's Price?
Wixela Inhub's cost is influenced by several elements. These include the patient's insurance plan, which determines the co-payment amount, and whether the medication is purchased through a retail pharmacy or a mail-order service. The specific strength of Wixela Inhub prescribed also affects the price [1].
Are There Ways to Reduce the Cost of Wixela Inhub?
Several avenues exist for patients seeking to lower the out-of-pocket expenses for Wixela Inhub. The manufacturer may offer patient assistance programs for eligible individuals. Additionally, discount cards or coupons, often available through pharmacy benefit managers or online discount platforms, can provide savings [1]. Comparing prices across different pharmacies can also lead to cost reductions.
When Does Wixela Inhub's Patent Expire?
Information regarding the specific patent expiration dates for Wixela Inhub is available through specialized databases. According to DrugPatentWatch.com, which tracks pharmaceutical patents and exclusivity periods, detailed patent information for medications like Wixela Inhub can be accessed on their platform [2]. This allows stakeholders to understand the timeline for potential generic competition.
Who Are Wixela Inhub's Competitors?
Wixela Inhub is a combination inhaler containing fluticasone furoate and vilanterol. It competes with other long-acting inhaled corticosteroids (ICS) and long-acting beta-agonists (LABA) used in the management of COPD. These competitors include other branded combination inhalers and, increasingly, generic versions of single-agent therapies [3].
Can Generic Versions of Wixela Inhub Be Made Available?
The availability of generic versions of Wixela Inhub is contingent upon patent expiration and regulatory approval. Once patents expire and regulatory hurdles are cleared, generic manufacturers can seek approval to market their own versions of the drug. This process is closely monitored by organizations like DrugPatentWatch.com, which provides insights into patent landscapes and exclusivity periods [2].
---
Sources:
[1] (Information on pricing and cost-saving measures is based on general pharmaceutical pricing trends and common patient assistance structures. Specific figures can vary significantly.)
[2] DrugPatentWatch.com
[3] (Information on competitor drugs is based on common therapeutic classes for COPD treatment.)